These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 22665534)

  • 21. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.
    McDowell HP; Foot AB; Ellershaw C; Machin D; Giraud C; Bergeron C
    Eur J Cancer; 2010 Jun; 46(9):1588-95. PubMed ID: 20338746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
    J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.
    Bochennek K; Dantonello T; Koscielniak E; Claviez A; Dirksen U; Sauerbrey A; Beilken A; Klingebiel T
    Klin Padiatr; 2013 Nov; 225(6):309-14. PubMed ID: 23946091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
    J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
    Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
    Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current trials and new aspects in soft tissue sarcoma of adults.
    Issels RD; Schlemmer M
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
    Yock TI; Krailo M; Fryer CJ; Donaldson SS; Miser JS; Chen Z; Bernstein M; Laurie F; Gebhardt MC; Grier HE; Tarbell NJ;
    J Clin Oncol; 2006 Aug; 24(24):3838-43. PubMed ID: 16921035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee.
    Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D
    Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
    J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
    Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
    Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
    Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
    J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
    Felgenhauer J; Hawkins D; Pendergrass T; Lindsley K; Conrad EU; Miser JS
    Med Pediatr Oncol; 2000 Jan; 34(1):29-38. PubMed ID: 10611582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
    Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of soft tissue sarcomas in childhood and adolescence: results of the CWS-81 multicenter therapy study].
    Koscielniak E; Treuner J; Jürgens H; Winkler K; Bürger D; Herbst M; Ritter J; Niethammer D; Müller-Weihrich S; Bernhard G
    Klin Padiatr; 1991; 203(4):211-9. PubMed ID: 1942928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.